Results 181 to 190 of about 5,702,542 (372)

Contemporary Perspectives on Chronic Renal Disorders

Chronic Diseases and Translational Medicine, EarlyView.
ABSTRACT The prevalence of renal diseases and its associated burden on healthcare have tremendously risen in the past few years. From simple markers assessing kidney function, current renal research delves into understanding the diseases at the cellular and molecular levels and not just at treating, but at improving quality of life, arresting ...
Deenadhayalan Ashok, Poornima Ajay Manjrekar, Bhushan C. Shetty, Sujina S. S, Rukmini Mysore Srikantiah, Sowndarya Kollampare   +5 more
wiley   +1 more source

Multiple Myeloma and Normal Pregnancy [PDF]

, 1966
Leonard Kosova, Steven O. Schwartz
openalex   +1 more source

Replacing a Cereblon Ligand by a DDB1 and CUL4 Associated Factor 11 (DCAF11) Recruiter Converts a Selective Histone Deacetylase 6 PROTAC into a Pan‐Degrader

ChemMedChem, EarlyView.
This study introduced DCAF11 as an E3 ligase for PROTAC‐mediated histone deacetylase (HDAC) degradation. By replacing cereblon with DCAF11 as recruited E3 ligase, a selective HDAC6 degrader (A6) was transformed into pan‐HDAC degraders. The lead compound, 1j (FF2039), potently degraded HDACs from classes I, IIa, and IIb, showing strong antiproliferative
Felix Feller, Heiko Weber, Martina Miranda, Irina Honin, Maria Hanl, Finn K. Hansen   +5 more
wiley   +1 more source

Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials

Haematologica, 2014
Elisabet E Manasanch, Neha Korde, Sham Mailankody, Nishant Tageja, Manisha Bhutani, Mark Roschewski, Ola Landgren   +6 more
doaj   +1 more source

The Role of Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Multiple Myeloma: Is It Time to Rethink the Paradigm in the Era of Targeted Therapy?

Hemato
High-dose melphalan (HDM) plus autologous stem cell transplant (ASCT) remains a standard-of-care treatment approach for eligible patients with newly diagnosed multiple myeloma (NDMM) based on demonstrated superiority in terms of progression-free survival
Paul G. Richardson
doaj   +1 more source

Chromosomal Abnormalities in Multiple Myeloma [PDF]

, 1967
Kinsuk Das, B. K. Aikat
openalex   +1 more source

Multiple-myeloma proteins.III. The antigenic relationship of Bence Jones proteins to normal gamma-globulin and multiple-myeloma serum proteins

, 1956
Leonhard Korngold, Rose Lipari
openalex   +1 more source

Disc Electrophoresis Study of Serum Proteins from Patients with Multiple Myeloma and Macroglobulinemia [PDF]

, 1963
Salvador B. Zingale, Carlos A. Mattioli, HANS D. BOHNER, MARÍA P. BUENO   +3 more
openalex   +1 more source

A Novel Two‐Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Cytokine release syndrome (CRS) is a common, acute adverse event associated with T‐cell redirecting therapies such as bispecific antibodies (BsAbs). The nature of CRS events data makes it challenging to capture an unbiased exposure–response relationship with commonly used models.
Donald Irby, Jennifer Hibma, Mohamed Elmeliegy, Diane Wang, Erik Vandendries, Kamrine Poels, Blerta Shtylla, Jason H. Williams   +7 more
wiley   +1 more source

Evolving Recommendations for Patient Populations Among Oncology Medicines: A Quantitative and Qualitative Analysis

Clinical Pharmacology &Therapeutics, EarlyView.
After a medicine has been tested in pivotal trials, regulators, health technology assessment (HTA) organizations, and professional societies make decisions about the patients best served by the medicine. This study assesses how the patient populations for oncology medicines (2010–2023) are defined (1) at trial, (2) regulatory submission, (3) upon ...
Milou A. Hogervorst, Rick A. Vreman, Theresa A. Oduol, Aukje K. Mantel‐Teeuwisse, Wim G. Goettsch, Aaron S. Kesselheim   +5 more
wiley   +1 more source